Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.

September 2018 Issue of The Medicine Maker

“Industry 4.0 – what does it mean and why should biopharma care? In this month’s cover feature we ask biopharma industry experts for their view. Meanwhile, Upfront looks at a new not-for-profit company headed up by Power List alumni Martin Van Trieste, and a paper-based assay for spotting fake antibiotics. But in In My View, Maarten Van Baelen considers the unintended consequences of fighting counterfeit medicine… Also in this issue we find out what pharma can learn from Toyota in lean manufacturing, and how sharks can influence a new generation of biotherapeutics. Finally, we Sit Down With Danny Bar-Zohar, Global Head of Neuroscience Development at Novartis, Switzerland.”

Register to download

Register here to download any issue of The Medicine Maker for FREE.

Login if you already created an account

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login as a Guest or via Social Media

Articles featured in this issue

Manufacture

Science Versus Sensationalism

| James Strachan

Don’t give the journalists an excuse to fuel the hype machine.

Business & Regulation

For Patients, Not Profits

A new not-for-profit company will manufacture important generics in the US

Manufacture

Just One Shot

| Stephanie Sutton

A vaccine using mRNA demonstrates potential for broad influenza protection.

Business & Regulation

Knowing Your Values

| Stephanie Sutton

Does a medicine’s price consistently track with its benefits and value? Not in the US, according to a study.

Business & Regulation

Let’s Talk About Mental Health

| Roisin McGuigan

A recent survey examined the relationships – or lack thereof – between pharma companies and mental health patient groups

Manufacture

Don’t Have Your Fake, or Eat It

| Joanna Cummings

Finding counterfeit antibiotics – using a color-changing paper test

Manufacture

Business-in-Brief

| Stephanie Sutton

After many years of clinical trial failures in Alzheimer’s disease, pharma sees some positive results – although caution is recommended.

Manufacture

A “Wellcome” Sight

| Joanna Cummings

A fresh take on an existing photography competition aims to display the diversity of science.

Manufacture

Trials of a Medicine Maker

Gene and Eva consider the importance of good record keeping.

Manufacture

The Costs of the Counterfeit Battle

| Maarten Van Baelen

Fighting counterfeit medicines is a noble goal, but the financial burden of safety features may affect access to medicines in unintended ways.

Manufacture

The CHO’s Over: An Inflexion Point

| Mark Emalfarb

Global healthcare costs and demands are changing, and it’s time to look beyond mammalian cell lines.

Manufacture

Right for Patients?

| Ellen Sigal

“Right to Try” legislation may have compassion at its heart, but it does not do enough to ensure patient protection.

Business & Regulation

Towards Industry 4.0

| James Strachan

The fourth industrial revolution – Industry 4.0 – represents a shift in manufacturing mentality. Is biopharma ready?

Business & Regulation

Kaizen Chiefs

| Chris Owen

The automotive sector – Toyota, in particular – is a rich source of inspiration for improving productivity.

Discovery & Development

Antibody About Turn

| Sam Cobb

A promising candidate is on the verge of entering clinical development… What happens when you see an opportunity to make it even better?

Manufacture

The Medicinal Chemistry Puzzle: Lessons Learned with James Hitchin

| James Hitchin

From big pharma, to cancer research to a fast growing CRO, James Hitchin has gained multiple perspectives on a subject that has become his passion – medicinal chemistry.

Discovery & Development

The Power to Change Lives

| Stephanie Sutton

Sitting Down With…Danny Bar-Zohar, Global Head of Neuroscience Development at Novartis, Switzerland

Business & Regulation

The Marijuana Medicine Makers

| Kevin Hennessy

Interest in cannabinoid drug development is growing. The potential market – and the opportunity to treat unmet patient needs – is enormous.

Discovery & Development

Returning to Spain

| Sponsored by CPHi

CPhI Worldwide will return on October 9-11, 2018, at the IFEMA, Feria de Madrid, Spain.

Manufacture

What Makes a “Good” Bioprocess?

| Sponsored by ThermoFisher Scientific

The development of an optimized bioprocess requires a holistic approach tailored to the specific needs of the product.

Other issues of 2018